Linked Life Data

14508090

Source:http://linkedlifedata.com/resource/pubmed/id/14508090

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4 Suppl 1
pubmed:dateCreated
2003-9-25
pubmed:abstractText
Angiogenesis inhibitors belong to a new class of drugs. Many of these drugs are in clinical trials to treat cancer, while others have recently received FDA approval. However, angiogenesis inhibitors operate by different mechanisms than conventional cytotoxic chemotherapies, and require different guidelines for their optimum use in animal models and in humans. Some of the more significant guidelines of antiangiogenic therapy are assembled in this chapter, and their scientific basis is discussed.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1538-4047
pubmed:author
pubmed:issnType
Print
pubmed:volume
2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S127-33
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:articleTitle
Angiogenesis inhibitors: a new class of drugs.
pubmed:affiliation
Harvard Medical School, Children's Hospital; Boston, Massachusetts 02115 USA. jadah.folkman@TCH.Harvard.edu
pubmed:publicationType
Journal Article, Review